Endophthalmitis Associated With XEN Stent Implantation.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
09 2023
Historique:
received: 28 12 2022
revised: 31 03 2023
accepted: 05 04 2023
pmc-release: 01 09 2024
medline: 18 8 2023
pubmed: 15 4 2023
entrez: 14 4 2023
Statut: ppublish

Résumé

The aim of this study is to report the clinical characteristics, causative organisms, and treatment outcomes in patients presenting with endophthalmitis related to XEN stent implants. Retrospective, noncomparative consecutive case series. Clinical and microbiologic review was performed for 8 patients presenting to the Bascom Palmer Eye Institute Emergency Room between 2021 and 2022 with XEN stent-related endophthalmitis. Data collected included clinical characteristics of patients at presentation, organisms identified in ocular cultures, treatments received, and visual acuity at last follow-up. The current study included 8 eyes from 8 patients. All cases of endophthalmitis occurred >30 days after implantation of the XEN stent. At the time of presentation, there were external exposures of the XEN stent in 4 of 8 patients. Five of the 8 patients had positive intraocular cultures, all of which were variants of staphylococcus and streptococcus species. Management included intravitreal antibiotics in all patients, explantation of the XEN stent in 5 patients (62.5%), and pars plana vitrectomy in 6 patients (75%). At last follow-up, 6 of the 8 patients (75%) had a visual acuity of hand motion or worse. Endophthalmitis in the setting of XEN stents results in poor visual outcomes. The most common causative organisms are staphylococcus or streptococcus species. At time of diagnosis, prompt treatment with broad-spectrum intravitreal antibiotics is recommended. Consideration can be made to explant the XEN stent and perform early pars plana vitrectomy.

Identifiants

pubmed: 37059319
pii: S0002-9394(23)00167-8
doi: 10.1016/j.ajo.2023.04.006
pmc: PMC10524262
mid: NIHMS1893425
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

37-43

Subventions

Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Références

J Glaucoma. 2022 Sep 1;31(9):744-750
pubmed: 35654366
J Curr Glaucoma Pract. 2021 Sep-Dec;15(3):153-160
pubmed: 35173399
Ophthalmic Surg Lasers Imaging Retina. 2021 Apr;52(4):182-189
pubmed: 34039183
J Glaucoma. 2022 Aug 1;31(8):675-681
pubmed: 35773233
Arch Ophthalmol. 1996 Aug;114(8):943-9
pubmed: 8694729
Ophthalmol Retina. 2021 Mar;5(3):279-284
pubmed: 32688083
PLoS One. 2020 Apr 20;15(4):e0231614
pubmed: 32310972
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):137-42
pubmed: 18766368
Clin Ophthalmol. 2021 Jan 26;15:299-305
pubmed: 33531795
Int J Ophthalmol. 2018 Mar 18;11(3):416-421
pubmed: 29600175
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1741-1750
pubmed: 31093766
Eye (Lond). 2021 Jul;35(7):1850-1858
pubmed: 33674726
Br J Ophthalmol. 2005 Apr;89(4):454-8
pubmed: 15774923
Clin Ophthalmol. 2020 Jun 30;14:1805-1832
pubmed: 32636610
J Curr Glaucoma Pract. 2020 Sep-Dec;14(3):87-92
pubmed: 33867756
Curr Opin Ophthalmol. 2012 Mar;23(2):96-104
pubmed: 22249233
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Ophthalmology. 2017 Nov;124(11):1579-1588
pubmed: 28601250
Ophthalmol Glaucoma. 2023 Jan-Feb;6(1):4-10
pubmed: 35843548
Cochrane Database Syst Rev. 2017 Feb 22;2:CD012131
pubmed: 28225198
Retina. 2017 Jun;37(6):1160-1167
pubmed: 27673715
Ophthalmology. 2018 May;125(5):650-663
pubmed: 29477688
Am J Ophthalmol. 2015 Sep;160(3):516-521.e2
pubmed: 26032191
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4789-95
pubmed: 26218906
Cochrane Database Syst Rev. 2020 Mar 9;3:CD012740
pubmed: 32147807
J Glaucoma. 2018 Feb;27(2):140-147
pubmed: 29271806
Ophthalmology. 2001 Jul;108(7):1323-7
pubmed: 11425695
Ophthalmol Glaucoma. 2021 Mar-Apr;4(2):193-200
pubmed: 32931947
Ophthalmology. 2015 Aug;122(8):1615-24
pubmed: 26092196
Ophthalmology. 2021 Dec;128(12):1777-1779
pubmed: 34102231
Eye Vis (Lond). 2019 Sep 29;6:29
pubmed: 31583261

Auteurs

Benjamin R Lin (BR)

From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.

Hasenin Al-Khersan (H)

From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.

Elena Bitrian (E)

From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.

Harry W Flynn (HW)

From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.. Electronic address: hflynn@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH